StockNews.com assumed coverage on shares of Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) in a report released on Thursday morning. The firm issued a strong-buy rating on the stock. Several other equities research analysts have also recently commented on NBIX. Piper Sandler dropped their target price on Neurocrine Biosciences from $103.00 to $95.00 and set a […]
Prudential PLC boosted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 159.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,898 shares of the company’s stock after purchasing an additional 3,628 shares during the period. Prudential PLC’s holdings in […]
Great Lakes Advisors LLC lessened its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 2.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 42,226 shares of the company’s stock after selling 878 shares during the […]
First Trust Advisors LP trimmed its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 11.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 673,718 shares of the company’s stock after selling 91,049 shares during the quarter. First Trust Advisors […]
Impax Asset Management Group plc lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 16.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 175,000 shares of the company’s stock after purchasing an additional 25,000 shares during the period. Impax […]